AGE1.CR.REX
LIVE

Serial Number

79445291

Owner

ProBioGen AG

Filing Date

Jan 13, 2026

Add to watchlist:

No watchlists yet
View on USPTO

AGE1.CR.REX Trademark

Serial Number: 79445291

AGE1.CR.REX is a trademark filed by ProBioGen AG on January 13, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently pending registration.

Owner Contact Info

ProBioGen AG (10 trademarks)

Goethestr. 54

Entity Type: 99

Trademark Details

Filing Date

January 13, 2026

Registration Date

Not Registered

Goods & Services

Licensing of intellectual property.

Biological preparations for diagnostic, pharmaceutical, medical and veterinary purposes, in particular preparations developed from biological cells; biological preparations for medical or veterinary purposes, in particular cell cultures, cell lines in the form of designer cell lines and cell substrates for pharmaceutical, medical and veterinary purposes, in particular for the manufacture of vaccines, proteins and other pharmaceutical agents; vaccines, antibodies and proteins for diagnostic, pharmaceutical, medicinal and veterinary purposes, in particular pharmaceutical agents for therapeutic, preventive and in vitro diagnostic applications.

Scientific and industrial biological research and development, namely, product development of proteins and vaccines using biological cells, including cell-line design; scientific laboratory services, namely, product development of proteins and vaccines with the aid of biological cells, including cell line design.

Filing History

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 4, 2026 RFCS
REFUSAL PROCESSED BY MPU
Jul 4, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 17, 2026 RFCR
NON-FINAL ACTION WRITTEN
May 16, 2026 CNRT
ASSIGNED TO EXAMINER
May 11, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 16, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 16, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 12, 2026 REPR